同步放化疗与单纯放疗对鼻咽癌患者近期及远期影响

目的：探讨同步放化疗与单纯放疗对鼻咽癌患者近期及远期影响。方法：选取我院2008年2月至2010年2月的156例鼻咽癌患者进行研究，随机分为同步放化疗组和单纯放疗组各78例，同步放化疗组采用奥沙利铂联合贝伐单抗与卡培他滨化疗2周期再进行放疗，单纯放疗组采用顺铂单纯放疗，观察两组患者的治疗效果，1、3、5年的生存率和局部控制率，并发症等指标。结果：同步放化疗组的有效率(92.3%)明显高于单纯放疗组(79.5%)，具有统计学意义(χ2=5.987，P<0.05)；同步化放疗组1、3、5年的局部控制率(76.9%、62.8%、48.7%)明显高于单纯放疗组(62.8%、48.7%、38.5%)，具有统计学意义(χ2=5.696，P=0.031；χ2=5.595，P=0.032；χ2=5.512，P=0.039)；同步化放疗组的1、3、5年的生存率(66.7%、56.4%、46.2%)明显高于单纯放疗组(56.4%、46.2%、35.9%)，具有统计学意义(χ2=5.396，P=0.033；χ2=5.356，P=0.034；χ2=5.445，P=0.031)；同步化放疗组的并发症发生率(5.1%)明显低于单纯放疗组(28.2%)，具有统计学意义(χ2=5.968，P<0.05)结论：对鼻咽癌患者进行同步化放疗能更好的控制病情，提高患者的生存率，减少不良反应的发生，比较安全。

Short- and long-term effects of concurrent radiotherapy and chemotherapy and radiotherapy alone for patients with nasopharyngeal carcinoma

Objective: To study the short- and long-term effects of concurrent radiotherapy and chemotherapy and radiotherapy alone for patients with nasopharyngeal carcinoma.Methods: From February 2008 to February 2010, selected 156 cases of patients with nasopharyngeal carcinoma (NPC) to study, which were randomly divided into concurrent radiotherapy and chemotherapy group and radiotherapy group (n=78 cases), the concurrent radiotherapy and chemotherapy group used by oxaliplatin into joint bevacizumab and capecitabine for 2 cycles of chemotherapy and radiotherapy, radiotherapy alone group was treated with cisplatin alone radiotherapy, observed the curative effect, 1-, 3- and 5-year survival rate and local control rate and complications indicators of two groups of patients.Results: The response rate of the chemoradiotherapy group (92.3%) was significantly higher than the radiotherapy group (79.5%), with statistical significance (χ2=5.987,P<0.05); 1-, 3-, 5-year local control rate of concurrent chemoradiotherapy group (76.9%, 62.8%, 48.7%) was significantly higher than those of the radiotherapy group (62.8%, 48.7%, 38.5%), with statistical signiifcance (χ2=5.696,P=0.031; χ2=5.595,P=0.032; χ2=5.512,P=0.039); 1-, 3-, 5-year survival rate (66.7%, 56.4%, 46.2%) of synchronized radiotherapy group was signiifcantly higher than the radiotherapy group (56.4%, 46.2%, 35.9%), with statistical signiifcance (χ2=5.396, P=0.033; χ2=5.445,P=0.034; χ2=5.356,P=0.031); the incidence of complications of synchronous radiotherapy group (5.1%) was signiifcantly lower than the radiotherapy group (28.2%), with statistical signiifcance (χ2=5.968, P<0.05).Conclusion: Synchronous radiotherapy for nasopharyngeal carcinoma patients can better control the disease, improve the survival rate of patients, and reduce the incidence of adverse reactions. It is relatively safe.